JP2009534458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534458A5 JP2009534458A5 JP2009507166A JP2009507166A JP2009534458A5 JP 2009534458 A5 JP2009534458 A5 JP 2009534458A5 JP 2009507166 A JP2009507166 A JP 2009507166A JP 2009507166 A JP2009507166 A JP 2009507166A JP 2009534458 A5 JP2009534458 A5 JP 2009534458A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- ring
- alkyl
- substituent
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 44
- 150000001875 compounds Chemical class 0.000 claims 41
- 125000001424 substituent group Chemical group 0.000 claims 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 21
- 229910052799 carbon Inorganic materials 0.000 claims 19
- 125000006413 ring segment Chemical group 0.000 claims 17
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 8
- 125000001931 aliphatic group Chemical group 0.000 claims 6
- 125000005488 carboaryl group Chemical group 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 4
- 230000000747 cardiac effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- OCLTYFPYUITULW-UHFFFAOYSA-N 2-[4-(2-azaniumylethylamino)quinazolin-2-yl]phenolate Chemical compound N=1C2=CC=CC=C2C(NCC[NH3+])=NC=1C1=CC=CC=C1[O-] OCLTYFPYUITULW-UHFFFAOYSA-N 0.000 claims 2
- RLPKZWZRWZAREY-UHFFFAOYSA-N 2-[4-[2-(dimethylamino)ethyl-methylamino]quinazolin-2-yl]phenol Chemical compound N=1C2=CC=CC=C2C(N(C)CCN(C)C)=NC=1C1=CC=CC=C1O RLPKZWZRWZAREY-UHFFFAOYSA-N 0.000 claims 2
- UHUSWNZAQNPVAZ-UHFFFAOYSA-N 2-[4-[benzyl-[2-(dimethylamino)ethyl]amino]quinazolin-2-yl]phenol Chemical compound N=1C(C=2C(=CC=CC=2)O)=NC2=CC=CC=C2C=1N(CCN(C)C)CC1=CC=CC=C1 UHUSWNZAQNPVAZ-UHFFFAOYSA-N 0.000 claims 2
- CPFPZLGOLAIPEJ-UHFFFAOYSA-N 2-[4-[methyl-[2-(methylamino)ethyl]amino]quinazolin-2-yl]phenol Chemical compound N=1C2=CC=CC=C2C(N(C)CCNC)=NC=1C1=CC=CC=C1O CPFPZLGOLAIPEJ-UHFFFAOYSA-N 0.000 claims 2
- BBPQTUSTRGCJFA-UHFFFAOYSA-N 2-[6-fluoro-4-[propan-2-yl-[2-(propan-2-ylamino)ethyl]amino]quinazolin-2-yl]phenol Chemical compound N=1C2=CC=C(F)C=C2C(N(C(C)C)CCNC(C)C)=NC=1C1=CC=CC=C1O BBPQTUSTRGCJFA-UHFFFAOYSA-N 0.000 claims 2
- TWBMKKRZEXYAEB-UHFFFAOYSA-N 2-[7-chloro-4-[propan-2-yl-[2-(propan-2-ylamino)ethyl]amino]quinazolin-2-yl]phenol Chemical compound N=1C2=CC(Cl)=CC=C2C(N(C(C)C)CCNC(C)C)=NC=1C1=CC=CC=C1O TWBMKKRZEXYAEB-UHFFFAOYSA-N 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000009621 actinic keratosis Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000010247 heart contraction Effects 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 238000007634 remodeling Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000008261 skin carcinoma Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 claims 1
- LUUPGXCMWMVHFT-UHFFFAOYSA-N 2-[4-[2-(2-aminoethylamino)ethylamino]-6-methylpyrimidin-2-yl]phenol Chemical compound CC1=CC(NCCNCCN)=NC(C=2C(=CC=CC=2)O)=N1 LUUPGXCMWMVHFT-UHFFFAOYSA-N 0.000 claims 1
- HCTKEZSDUAELKJ-UHFFFAOYSA-N 2-[4-[2-(2-aminoethylamino)ethylamino]quinazolin-2-yl]phenol Chemical compound N=1C2=CC=CC=C2C(NCCNCCN)=NC=1C1=CC=CC=C1O HCTKEZSDUAELKJ-UHFFFAOYSA-N 0.000 claims 1
- AYCDFEQEJDZWCW-UHFFFAOYSA-N 2-[4-[2-(diethylamino)ethylamino]quinazolin-2-yl]phenol Chemical compound N=1C2=CC=CC=C2C(NCCN(CC)CC)=NC=1C1=CC=CC=C1O AYCDFEQEJDZWCW-UHFFFAOYSA-N 0.000 claims 1
- FWDOFICFVFGQST-UHFFFAOYSA-N 2-[4-[2-(diethylazaniumyl)ethylamino]quinazolin-2-yl]-6-methoxyphenolate Chemical compound N=1C2=CC=CC=C2C(NCC[NH+](CC)CC)=NC=1C1=CC=CC(OC)=C1[O-] FWDOFICFVFGQST-UHFFFAOYSA-N 0.000 claims 1
- VSPUJENJRPYDDV-UHFFFAOYSA-N 2-[7-methyl-4-[propan-2-yl-[2-(propan-2-ylamino)ethyl]amino]quinazolin-2-yl]phenol Chemical compound N=1C2=CC(C)=CC=C2C(N(C(C)C)CCNC(C)C)=NC=1C1=CC=CC=C1O VSPUJENJRPYDDV-UHFFFAOYSA-N 0.000 claims 1
- ZAGIJQBZAGMVDG-UHFFFAOYSA-N CC1=CC(NCCN)=NC(C=2C(=CC=CC=2)O)=N1 Chemical compound CC1=CC(NCCN)=NC(C=2C(=CC=CC=2)O)=N1 ZAGIJQBZAGMVDG-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- PIXFXRFKDDZLIW-UHFFFAOYSA-N n-[2-(2,6-dimethoxyphenyl)quinolin-4-yl]-n',n'-dimethylethane-1,2-diamine Chemical compound COC1=CC=CC(OC)=C1C1=CC(NCCN(C)C)=C(C=CC=C2)C2=N1 PIXFXRFKDDZLIW-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 CN(*)C(*)(*)C(*)(*)N(*)* Chemical compound CN(*)C(*)(*)C(*)(*)N(*)* 0.000 description 6
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74563006P | 2006-04-26 | 2006-04-26 | |
| GB0608269A GB0608269D0 (en) | 2006-04-26 | 2006-04-26 | Therapeutic compounds |
| PCT/GB2007/001537 WO2007125331A2 (en) | 2006-04-26 | 2007-04-26 | Amino-ethyl-amino-aryl (aeaa) compounds and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009534458A JP2009534458A (ja) | 2009-09-24 |
| JP2009534458A5 true JP2009534458A5 (enExample) | 2010-06-17 |
Family
ID=38581449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009507166A Withdrawn JP2009534458A (ja) | 2006-04-26 | 2007-04-26 | アミノ−エチル−アミノ−アリール（ａｅａａ）化合物およびそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090247519A1 (enExample) |
| EP (1) | EP2024333A2 (enExample) |
| JP (1) | JP2009534458A (enExample) |
| AU (1) | AU2007245496A1 (enExample) |
| CA (1) | CA2649995A1 (enExample) |
| IL (1) | IL194899A0 (enExample) |
| MX (1) | MX2008013718A (enExample) |
| WO (1) | WO2007125331A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007328336B2 (en) * | 2006-12-01 | 2014-04-17 | President And Fellows Of Harvard College | Compounds and methods for enzyme-mediated tumor imaging and therapy |
| MX2009010127A (es) * | 2007-03-22 | 2009-11-05 | Vertex Pharma | Compuestos utiles como inhibidores de janus cinasas. |
| AU2009256645A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Pyrazine derivatives as epithelial sodium channel blockers |
| JP2011522865A (ja) * | 2008-06-13 | 2011-08-04 | ノバルティス アーゲー | Ｉａ心不全および癌の治療に有用なプロテインキナーゼｄ阻害剤としての２，４’−ビピリジニル化合物 |
| US20120122819A1 (en) * | 2009-06-12 | 2012-05-17 | Socpra - Sciences Et Genie S.E.C. | Guanine riboswitch binding compounds and their use as antibiotics |
| CN102574817A (zh) | 2009-09-24 | 2012-07-11 | 巴斯夫欧洲公司 | 用于抵抗无脊椎动物害虫的氨基喹唑啉化合物 |
| US8759363B2 (en) * | 2010-01-28 | 2014-06-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Quinazoline-based T cell proliferation inhibitors |
| WO2011119842A1 (en) | 2010-03-25 | 2011-09-29 | The J. David Gladstone Institutes | Compositions and methods for treating neurological disorders |
| EP3601267A1 (en) | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| CA3097231A1 (en) | 2018-04-18 | 2019-10-24 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
| AU2020332367A1 (en) * | 2019-08-22 | 2022-02-17 | Biohaven Therapeutics Ltd. | Molecules that bind to TDP-43 for the treatment of amyotrophic lateral sclerosis and related disorders |
| CN116323587A (zh) * | 2020-08-07 | 2023-06-23 | 阿索斯治疗公司 | 用于自身免疫疾病和癌症治疗的小分子 |
| EP4052700A1 (en) * | 2021-03-03 | 2022-09-07 | Instytut Biologii doswiadczalnej imienia Marcelego Nenckiego Polskiej Akademii Nauk | Inhibitor of protein kinase d (pkd) for use in prevention or treatment of obesity and a pharmaceutical composition for such use |
| US20240082260A1 (en) | 2021-03-03 | 2024-03-14 | Instytut Biologii doswiadczalnej imienia Marcelego Nenckiego Polskiej Akademii Nauk | Inhibitor of protein kinase d for use in prevention or treatment of hyperlipidemia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1377554A1 (en) | 1999-06-16 | 2004-01-07 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| DE60236322D1 (de) | 2001-12-07 | 2010-06-17 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| CL2004000409A1 (es) | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| MXPA06000051A (es) | 2003-07-02 | 2006-03-21 | Vertex Pharma | Pirimidinas utiles como moduladores de canales ionicos dependientes de voltaje. |
| CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
-
2007
- 2007-04-26 AU AU2007245496A patent/AU2007245496A1/en not_active Abandoned
- 2007-04-26 US US12/298,311 patent/US20090247519A1/en not_active Abandoned
- 2007-04-26 WO PCT/GB2007/001537 patent/WO2007125331A2/en not_active Ceased
- 2007-04-26 MX MX2008013718A patent/MX2008013718A/es not_active Application Discontinuation
- 2007-04-26 CA CA002649995A patent/CA2649995A1/en not_active Abandoned
- 2007-04-26 EP EP07732574A patent/EP2024333A2/en not_active Withdrawn
- 2007-04-26 JP JP2009507166A patent/JP2009534458A/ja not_active Withdrawn
-
2008
- 2008-10-23 IL IL194899A patent/IL194899A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534458A5 (enExample) | ||
| CN105906617B (zh) | Hec1活性调节剂及其方法 | |
| TWI469970B (zh) | 調節ｈｓｐ９０活性之咪唑化合物 | |
| JP6031122B2 (ja) | 抗微生物療法のための三環式ホウ素化合物 | |
| CA2381090A1 (en) | Benzoic acid derivatives for the treatment of diabetes mellitus | |
| CN101952257A (zh) | 苯并咪唑化合物 | |
| An et al. | The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer | |
| EP4116291A1 (en) | Synthesis of novel ep4 antagonist and use in cancers and inflammations | |
| JP2020506970A5 (enExample) | ||
| CN112279833A (zh) | 用于治疗癌症、视网膜病症和心肌病的三取代嘧啶化合物和组合物 | |
| US20160340321A1 (en) | Substituted 1,2,3-Triazoles as Antitumor Agents | |
| US20150191443A1 (en) | Griseofulvin derivatives | |
| US11787790B2 (en) | Benzimidazole derivative having fluorine-containing substituent, preparation and application thereof | |
| RU2510394C1 (ru) | Производное селеназола, имеющее лиганд, который активирует рецептор, активируемый пролифератором пероксисом ( ppar ), способ его получения и применение химических соединений | |
| US9902709B2 (en) | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | |
| BR112021015588A2 (pt) | Novos derivados de n-benzil-2-fenoxibenzamida como moduladores de receptores de prostaglandina e2 (pge2) | |
| US10738047B2 (en) | Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulations thereof; and uses thereof | |
| WO2019105234A1 (zh) | 芳香族化合物及其药物组合物和用途 | |
| JPWO2020219650A5 (enExample) | ||
| JP7679090B2 (ja) | 置換ヒドロキシスチルベン化合物および誘導体、合成ならびにそれらの使用 | |
| BR112019009801A2 (pt) | 4-((6-(2-(2,4-difluorofenil)-1,1-difluoro-2-hidróxi-3-(5-mercapto-1h-1,2,4-triazol-1-il)propil)piridin-3-il)óxi)benzonitrila e processos de preparação | |
| JP2013536204A (ja) | ベルバミンのジカルボキシミド誘導体、その調製方法及び使用 | |
| CN105481781B (zh) | 化合物及其制备方法和应用 | |
| US10774046B2 (en) | Inhibitors for the treatment of cancer and related methods | |
| CN116535304A (zh) | 毛兰素类似物及其合成方法和应用 |